Accessibility Menu
Calliditas Therapeutics Ab (publ) logo

Calliditas Therapeutics Ab (publ)

(NASDAQ) CALT

This security has been delisted. This page is retained for historical reference.

CALT News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

CALT Financials

Key Financial Metrics (TTM)

Gross Margin

93.62%

Operating Margin

-31.85%

Net Income Margin

-38.63%

Return on Equity

-84.68%

Return on Capital

-29.26%

Return on Assets

-24.53%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

SEK 1.50B

Operating Income

-SEK 368.18M

EBITDA

-SEK 358.56M

Operating Cash Flow

-SEK 244.93M

Capital Expenditure

-SEK 12.79M

Free Cash Flow

-SEK 257.72M

Cash & ST Invst.

SEK 797.28M

Total Debt

SEK 1.01B

Calliditas Therapeutics Ab (publ) Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2024YOY CHG

Revenue

SEK 559.78M

+107.8%

Gross Profit

SEK 506.33M

+98.4%

Gross Margin

90.45%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

222

N/A

Net Income

-SEK 47.48M

+48.4%

EBITDA

-SEK 28.81M

+61.4%

Quarterly Fundamentals

Name
Q2 2024YOY CHG

Total Cash

SEK 797.28M

-8.0%

Total Debt

SEK 1.01B

+29.3%

Accounts Receivable

SEK 317.02M

+38.0%

Inventory

SEK 40.16M

+127.0%

Long Term Debt

SEK 1.01B

+29.3%

Short Term Debt

SEK 0.00

N/A

Return on Assets

-24.53%

N/A

Return on Invested Capital

-25.74%

N/A

Free Cash Flow

-SEK 7.04M

+95.7%

Operating Cash Flow

-SEK 7.04M

+95.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DICEDICE Therapeutics, Inc.
$47.55+0.06%
LBPHLongboard Pharmaceuticals, Inc.
$59.98N/A
BLUBELLUS Health Inc.
$14.75+0.03%
PRVBProvention Bio, Inc.
$24.98+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOFISoFi Technologies
$18.78+0.01%
PATHUiPath
$11.68-0.01%
FRMIFermi
$6.59-0.10%
ONDSOndas
$7.26-0.05%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.